What Geltor makes
Geltor describes itself as a biotech company that designs peptides and polypeptides and produces them without animal inputs. Its portfolio covers beauty and personal care, specialty nutrition, and medical and life sciences. The company was started by Nick Ouzounov and Alex Lorestani, who met as doctoral students in a molecular biology lab at Princeton, and Lorestani serves as chief executive.
The founders have said they were frustrated that animal-derived inputs and harsh chemical processes remained common in industry. Geltor now frames its mission as using biodesign to make protein ingredients that are sustainable, ethically sourced and effective. A 2024 press release describes the company as California-based, and facility details can be confirmed in supplier due diligence.
Collagen is the central protein family. Collagen from cattle, pigs and fish is the raw material for conventional gelatin, so an animal-free collagen polypeptide is relevant to the topic of animal-free gelatin. Geltor’s own materials, however, position its products as ingredients for skin, hair and ingestible beauty supplements, not as gelling agents for confectionery or dairy desserts.
The biodesign platform
The platform page lists six stages. Inspiration combines customer needs with biology knowledge. Biodesign selects and optimises amino acid sequences from computational databases of natural protein sequences. Fermentation uses microorganisms as protein factories at commercial scale, and purification separates the protein from the broth. Substantiation and function testing follow, and the last stage supports incorporation into finished products.
Geltor says this platform can deliver new protein ingredients in months rather than years and is built to work across proteins beyond collagen. It also describes its products as GMO-free because the final ingredient contains no host organism or genetic material. Yields, titres and volumes decide cost and scale, so those questions go to the company.
A funding announcement from July 2020 reported 91.3 million dollars of Series B capital to expand what the company called its ingredients-as-a-service platform globally. That figure comes from the company’s own press archive. The same archive lists the launch of Elastapure in April 2020, NuColl for hair care in January 2023 and Caviance in June 2023.
Product range
PrimaColl is a biomimetic collagen described as the most versatile grade, offered for topical and ingestible use. The company calls it the first FDA GRAS-cleared biodesigned collagen and cites GRAS Notice No. 1171 together with a no-questions letter, announced in October 2025. Listed applications include skin rejuvenation, comfort and resilience, hair manageability and gum health.
HumaColl21 is a biomimetic human type 21 collagen, described as a signaling collagen for topical skin products that aims to firm skin and reduce the look of wrinkles. A newer grade, HumaColl21 Select, is a type 21 matrikine complex made by precision proteolysis and was introduced in March 2026. Both are topical, and each carries its own cosmetic ingredient name.
Elastapure is a biomimetic human elastin polypeptide for skin and hair follicle care. Collume is a vegan collagen with a marine-inspired sequence that forms flexible films, and Caviance is described as a vegan type II collagen for topical beauty. These grades suit cosmetic formulators, and the website mentions colour cosmetics, oral care, intimate care and follicle care as product categories.
Certifications and recognition
The website lists portfolio-level marks rather than product-specific ones. They include Made with Fermentation, Vegan, Cruelty Free, Halal, Clean Beauty and Non-GMO. The about page adds the Vegan Trademark, a Silver EcoVadis sustainability rating, Non-GMO verification and Certified BioBased status. The only product-specific regulatory item shown is the GRAS notice for PrimaColl.
Recent news includes a 2026 Cosmetics and Toiletries award for PrimaColl in the wellness active category and an April 2026 launch of a vegan signaling collagen liquid supplement made with the partner TOSLA. The company also lists earlier recognition such as innovation awards from beauty industry bodies. Awards describe positioning and market reception, not technical performance of the ingredient.
Because PrimaColl is cleared in the United States for food use under a GRAS notice, a formulator in other regions should check local status separately. The pages reviewed describe no approvals in the European Union or other markets for ingestible use. Novel food rules differ by jurisdiction, so ask the supplier for a regulatory statement per market.
What a buyer would check
Start with the specification. A food or supplement formulator needs protein content, molecular weight distribution, amino acid profile, solubility, pH of solution, residual host protein and endotoxin limits, and heavy metal data. Ask which grade is cleared for ingestion and at which use levels, because the topical grades are not described as food ingredients.
Next, define the function. A collagen polypeptide of this kind is typically a nutritional or signaling ingredient, not a gelling protein, so a developer seeking gelatin replacement needs bloom strength and gel setting data that the pages do not provide. Request application trials in the target matrix, and compare sensory impact, colour and solubility with hydrolysed bovine or marine collagen.
Finally, review supply and claims. Ask about commercial batch sizes, lead times, the contract manufacturer used for fermentation and the stability of the supply chain. Check how health claims are substantiated for the target market, since wording that is acceptable on a cosmetic label may not be permitted on a food or supplement label in another region.